Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 488  

 
   Table of Contents      
EDITORIAL
Year : 2011  |  Volume : 10  |  Issue : 1  |  Page : 5-6

1 st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT), June 23-26, 2011, Zentralklinik Bad Berka, Germany


1 Prof. Richard Baum, Clinical Director, Zentralklinik Bad Berka, Germany
2 Institute of Nuclear Chemistry, University of Mainz, Germany

Date of Web Publication16-Jun-2011

Correspondence Address:
Richard P Baum
Prof. Richard Baum, Clinical Director, Zentralklinik Bad Berka
Germany
Richard P Baum
Prof. Richard Baum, Clinical Director, Zentralklinik Bad Berka
Germany
Login to access the Email id


DOI: 10.4103/1450-1147.82105

PMID: 22034575

Rights and Permissions

How to cite this article:
Baum RP, Rösch F, Baum RP, Rösch F. 1 st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT), June 23-26, 2011, Zentralklinik Bad Berka, Germany. World J Nucl Med 2011;10:5-6

How to cite this URL:
Baum RP, Rösch F, Baum RP, Rösch F. 1 st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT), June 23-26, 2011, Zentralklinik Bad Berka, Germany. World J Nucl Med [serial online] 2011 [cited 2020 Sep 24];10:5-6. Available from: http://www.wjnm.org/text.asp?2011/10/1/5/82105

Since the decoding of the human genome a decade ago, medicine has been rapidly moving toward a preventive and personalized mode focused on genetic and molecular diagnostics and targeted, individualized therapies.

Theranostics is the emerging field of molecular targeting of vectors which can be used for both therapies and diagnosis, when modified accordingly. This term was specifically used in the context of certain radiopharmaceuticals, so that the same pharmaceutical (e.g., a peptide), when labeled with a positron emitter can be used for diagnosis using PET/CT, and when labeled with a beta emitter may be used for therapy of a particular disease, targeted specifically by that radiopharmaceutical. The importance of Theranostics is that it takes into account personalized management of disease. Theranostics embodies both molecular and personalized medicine. [1],[2]

The 1 st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT) taking place in Bad Berka, Germany, from June 23 to 26, 2011, is co-organized by the Department of Nuclear Medicine/PET Center, Zentralklinik Bad Berka, and the Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany. Target audience include chemists, physicians, and investigators dealing with generators, PET radiochemistry as well as molecular imaging and radionuclide therapy.

The congress plans to both educate and offer a unique forum for high-level scientific discussions on the recent developments in the exciting field of Theranostics. A special focus is the rapidly developing research and clinical applications of Ga-68 and other generator-produced PET radioisotopes, new PET radiopharmaceuticals as well as PRRNT.

For 68 Ga radiopharmaceutical chemistry, this World Congress intends to reflect the first decade of the renaissance of 68 Ge/ 68 Ga radionuclide generators. The last 10 years of commercially available ionic generators have stimulated both systematic chemical research and clinical applications of promising tracers. [3],[4]

Outstanding speakers from all over the world will be giving their fascinating insights into their research and clinical work, creating new ideas and concepts on the way to personalized medicine. Within the next decade, further and rapid developments may be expected.

A considerable number of companies are participating in the Trade Exhibition, presenting the latest technological developments in generator technology and Ga-68 modules, devices and labeling strategies.

In addition, a "Hands-on Training Course" on 68 Ge/ 68 Ga generators for learning the practical principles of 68 Ge/ 68 Ga radionuclide generator elution for all types of today's available commercial systems, for eluate post-processing and 68 Ga labeling procedures as well as for product purification, combined with those of analogue 90 Y and 177 Lu chemistry is offered (for a limited number of participants) on June 27-28, 2011, at the Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany. In addition, this Training Course - as well as the World Congress itself - realizes the idea of transferring novel technologies to the member states of the IAEA, thus contributing to the concept of translating 68 Ge/ 68 Ga generators and PPRNT all over the world.

 
   References Top

1.Baum RP, Prasad V, Hommann M, Hörsch D. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res. 2008;170:225-42.  Back to cited text no. 1
    
2.Rosch F, Baum RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: On the way to THERANOSTICS. Dalton Trans 2011;40:6104-11.  Back to cited text no. 2
    
3.Roesch F, Riss PJ. The Renaissance of the 68 Ge/ 68 Ga radionuclide generator initiates new developments in 68 Ga radiopharmaceutical chemistry. Curr Top Med Chem 2010;10:1633-68.  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  
4.Baum RP, Prasad V. PET and PET/CT Imaging of Neuroendocrine Tumors. In: Wahl RL, editor. Principles and Practice of PET and PET/CT. 2nd Ed. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins; 2008. p. 411-37.  Back to cited text no. 4
    



This article has been cited by
1 PSMA diagnostics and treatments of prostate cancer become mature
Finn Edler von Eyben,Glenn Stewart Baumann,Richard Paul Baum
Clinical and Translational Imaging. 2018; 6(2): 145
[Pubmed] | [DOI]
2 Evaluation of excitation functions of the 68,67,66Zn(p,xn)68,67,66Ga and 67Zn(p,a)64Cu reactions: Validation of evaluated data through comparison with experimental excitation functions of the natZn(p,x)66,67Ga and natZn(p,x)64Cu processes
M.N. Aslam,N. Amjed,S.M. Qaim
Applied Radiation and Isotopes. 2015; 96: 102
[Pubmed] | [DOI]
3 Clinical applications of Gallium-68
Sangeeta Ray Banerjee,Martin G. Pomper
Applied Radiation and Isotopes. 2013; 76: 2
[Pubmed] | [DOI]
4 Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results
R Schoffelen,O C Boerman,D M Goldenberg,R M Sharkey,C M L van Herpen,G M Franssen,W J McBride,C-H Chang,E A Rossi,W T A van der Graaf,W J G Oyen
British Journal of Cancer. 2013; 109(4): 934
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed2775    
    Printed226    
    Emailed0    
    PDF Downloaded104    
    Comments [Add]    
    Cited by others 4    

Recommend this journal